(Q37107555)

18 August 2017

The natural history of noncastrate metastatic prostate cancer after radical prostatectomy (English)

1 reference

18 August 2017

1 reference

5

Howard I Scher

1 reference

18 August 2017

Ofer Yossepowitch

1

1 reference

18 August 2017

Fernando J Bianco

2

1 reference

18 August 2017

Scott E Eggener

3

1 reference

18 August 2017

James A Eastham

4

1 reference

18 August 2017

Peter T Scardino

6

1 reference

18 August 2017

language of work or name

English

0 references

publication date

30 October 2006

1 reference

18 August 2017

1 reference

18 August 2017

51

1 reference

18 August 2017

4

1 reference

18 August 2017

940-7; discussion 947-8

1 reference

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

Androgen deprivation therapy for prostate cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

Natural history of progression after PSA elevation following radical prostatectomy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

Ten-year survival in patients with metastatic prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

Impact of previous local treatment for prostate cancer on subsequent metastatic disease

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646889

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

3 September 2018

1 reference

12 December 2020

Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure

1 reference

12 December 2020

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

1 reference

12 December 2020

Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy

1 reference

12 December 2020

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

12 December 2020

Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer

1 reference

12 December 2020

10.1016/J.EURURO.2006.10.045

Identifiers

DOI

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

17125912

1 reference